LifeMD’s Strategic Positioning and Financial Health Reinforce Buy Rating Despite Revenue Miss

Tip Ranks
2025.11.19 16:35
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Yi Chen reiterated a Buy rating for LifeMD (LFMD) stock, despite a slight miss in Q3 revenue projections. LifeMD showed year-over-year growth in telehealth revenue and an increase in active subscribers. The company divested its majority ownership in WorkSimpli, enhancing its focus on telehealth and pharmacy. LifeMD's financial health is strong, with a solid cash position and no long-term debt. Chen set a 12-month price target of $9 for LFMD.

H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on LFMD stock, giving a Buy rating today.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

Yi Chen has given his Buy rating due to a combination of factors that highlight LifeMD’s strategic positioning and financial performance. Despite a slight miss in third-quarter revenue projections, LifeMD demonstrated a year-over-year growth in telehealth revenue and an increase in its active subscriber base. The company’s decision to divest its majority ownership in WorkSimpli has positioned it as a focused telehealth and pharmacy platform, which is expected to drive future growth.
Furthermore, LifeMD’s financial health is underscored by its cash position and the complete payoff of its long-term debt, which enhances its financial flexibility. The company’s adjusted EBITDA performance and updated revenue guidance reflect its resilience amid competitive pressures in the weight management market. Based on these factors and a valuation analysis using an EV/Revenue multiple, Yi Chen has set a 12-month price target of $9, reiterating the Buy rating for LifeMD.

Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, Formycon AG, and VolitionRX. According to TipRanks, Chen has an average return of -6.9% and a 39.44% success rate on recommended stocks.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.